Sugi Predict

Sugi Predict / Compounds / SCHEMBL4254374

SCHEMBL4254374

SCHEMBL4254374

Cc1ccc(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2CCCN(S(=O)(=O)c3ccccc3C#N)CC2)s1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ UTS2R Q9UKP6 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ CTSK P43235 6/20 0.39
▸ CTSL P07711 5/20 0.39
▸ CTSS P25774 4/20 0.39
▸ CTSB P07858 3/20 0.39
▸ CTSV O60911 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075417 0.88 KDM4E (0.45) ATMCTSKCTSLCTSSKDM4E
SCHEMBL5523428 0.88 UTS2R (0.54) UTS2RCTSKCTSLCTSSCTSB
SCHEMBL14342616 0.88 UTS2R (0.54) UTS2RCTSKCTSLCTSSCTSB
SCHEMBL4253479 0.88 UTS2R (0.54) UTS2RCTSKCTSLCTSSCTSB
SCHEMBL14342615 0.85 ATM (0.46) ATMKDM4EEPHX2CTDSP1TDP1
SCHEMBL4080686 0.85 CTSK (0.43) UTS2RATMCTSKCTSLCTSS
SCHEMBL4252303 0.83 CTSK (0.58) UTS2RCTSKCTSLCTSSCTSB
SCHEMBL4075475 0.83 ATM (0.40) UTS2RATMCTSKCTSLCTSS
SCHEMBL4077783 0.82 ATM (0.47) ATMKDM4EEPHX2CTDSP1TDP1
SCHEMBL14342619 0.82 CTSL (0.48) UTS2RATMCTSKCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796793-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-08-05 — — EP claimed
US-20070293477-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2007-12-20 — — US claimed
EP-1796793-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-20 — — EP claimed
WO-2006029154-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 — — WO claimed
EP-1796793-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-08-05 — — EP disclosed
US-20070293477-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2007-12-20 — — US disclosed
US-20070293477-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2007-12-20 — — US disclosed
US-20070293477-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2007-12-20 — — US disclosed
EP-1796793-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-20 — — EP disclosed
WO-2006029154-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293477-A1 Novel Compounds HRH4, TRPV4, TRPC4 UTS2R 315/4885ATM 4424/4885CTSK 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.